| HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing … S Modi, A Stopeck, H Linden, D Solit, S Chandarlapaty, N Rosen, ... Clinical Cancer Research 17 (15), 5132-5139, 2011 | 492 | 2011 |
| Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer AW Tolcher, S Sugarman, KA Gelmon, R Cohen, M Saleh, C Isaacs, ... Journal of Clinical Oncology 17 (2), 478-478, 1999 | 343 | 1999 |
| Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. R Pazdur, Y Lassere, V Rhodes, JA Ajani, SM Sugarman, YZ Patt, ... Journal of clinical oncology 12 (11), 2296-2300, 1994 | 268 | 1994 |
| Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients G Deng, AJ Vickers, KS Yeung, GM D'Andrea, H Xiao, AS Heerdt, ... Journal of clinical oncology 25 (35), 5584-5590, 2007 | 249 | 2007 |
| Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib PG Morris, C Chen, R Steingart, M Fleisher, N Lin, B Moy, S Come, ... Clinical Cancer Research 17 (10), 3490-3499, 2011 | 152 | 2011 |
| Identification of tamoxifen–DNA adducts in the endometrium of women treated with tamoxifen S Shibutani, A Ravindernath, N Suzuki, I Terashima, SM Sugarman, ... Carcinogenesis 21 (8), 1461-1467, 2000 | 151 | 2000 |
| Tamoxifen− DNA adducts detected in the endometrium of women treated with tamoxifen S Shibutani, N Suzuki, I Terashima, SM Sugarman, AP Grollman, ... Chemical research in toxicology 12 (7), 646-653, 1999 | 111 | 1999 |
| A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer K Jhaveri, S Chandarlapaty, D Lake, T Gilewski, M Robson, S Goldfarb, ... Clinical breast cancer 14 (3), 154-160, 2014 | 110 | 2014 |
| The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer C Dang, M Fornier, S Sugarman, T Troso-Sandoval, D Lake, G D'Andrea, ... Journal of clinical oncology 26 (8), 1216-1222, 2008 | 83 | 2008 |
| Phase II trial of the Hsp90 inhibitor tanespimycin (Tan)+ trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) S Modi, S Sugarman, A Stopeck, H Linden, W Ma, K Kersey, RG Johnson, ... Journal of Clinical Oncology 26 (15_suppl), 1027-1027, 2008 | 72 | 2008 |
| Consolidative use of radiotherapy to block (CURB) oligoprogression―interim analysis of the first randomized study of stereotactic body radiotherapy in patients with … CJ Tsai, JT Yang, DM Guttmann, N Shaverdian, AF Shepherd, J Eng, ... International Journal of Radiation Oncology* Biology* Physics 111 (5), 1325-1326, 2021 | 65 | 2021 |
| Phase II trial of docetaxel (Taxotere®) in metastatic colorectal carcinoma R Pazdur, Y Lassere, LT Soh, JA Ajani, B Bready, E Soo, S Sugarman, ... Annals of oncology 5 (5), 468-470, 1994 | 64 | 1994 |
| Liposomes in the treatment of malignancy: a clinical perspective SM Sugarman, R Perez-Soler Critical reviews in oncology/hematology 12 (3), 231-242, 1992 | 58 | 1992 |
| Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu–overexpressed/amplified breast cancer is not feasible … C Dang, N Lin, B Moy, S Come, S Sugarman, P Morris, A Abbruzzi, ... Journal of clinical oncology 28 (18), 2982, 2010 | 54 | 2010 |
| Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies SM Sugarman, YY Zou, K Wasan, K Poirot, R Kumi, S Reddy, ... Cancer chemotherapy and pharmacology 37, 531-538, 1996 | 50 | 1996 |
| Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results … LM Smyth, NM Iyengar, MF Chen, SM Popper, S Patil, ... Breast cancer research and treatment 158, 91-97, 2016 | 43 | 2016 |
| Lipid complexed topoisomerase I inhibitors R Perez-Soler, SM Sugarman, KR Poirot US Patent 5,834,012, 1998 | 42 | 1998 |
| Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies S Madajewicz, P Hentschel, P Burns, R Caruso, J Fiore, M Fried, ... Journal of clinical oncology 18 (20), 3553-3557, 2000 | 40 | 2000 |
| Role of adjuvant therapy in surgically resected colorectal carcinoma FA Sinicrope, SM Sugarman Gastroenterology 109 (3), 984-993, 1995 | 40 | 1995 |
| Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction PG Morris, M Dickler, HL McArthur, T Traina, S Sugarman, N Lin, B Moy, ... Journal of Clinical Oncology 27 (36), 6117, 2009 | 35 | 2009 |
